Medium1/2 relationships sourcedProfile verified Aug 13, 2026

30-Second Executive Brief

Executive Assessment

Fountain Life functions as a regional institution within Healthcare & Life Sciences, backed by 55% sourcing coverage, with a stable competitive position.

  • Maintains 2 mapped relationships across the graph
  • 55% sourcing coverage across sourced relationships
  • Tracked as regional institution within the Healthcare & Life Sciences category

Executive Snapshot

Strategic Role
Regional Institution
Sourcing Coverage
55%
View Methodology →

Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.

Ecosystem Influence
Moderate
Strategic Momentum
Insufficient Data

Coverage

Mapped Relationships
2
Technology Domains
4

Strategic Implications

  • Central node connecting multiple strategic ecosystems
  • Directly influences technology and capital flows
  • Material relevance to downstream dependency mapping

Top Opportunities

Planned expansion into Houston, Los Angeles, and Miami would roughly double Fountain Life's US clinic footprint

Top Risks

Premium pricing ($5,000-$25,000 per visit) limits total addressable market relative to lower-priced diagnostics competitors

Critical Dependencies

Continue to Dependency Graph ↓

A US preventive-health and longevity company offering executive physicals with bespoke consultations and diagnostic testing priced between $5,000 and $25,000 per visit, positioned at the high end of the personalized-diagnostics market Lifecore also competes in.

Sources

Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.

Evidence

2 sources

  • CB InsightsFountain Life offers premium executive physicalsresearch
  • IndexBoxFountain Life Secures $18M Series B for Longevity Center Expansionnews

Acquisition & Investment Fit

AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.

Relationship Map

The relationships surrounding Fountain Life — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.

Connection type

Sign in free to click a node and explore →

Click any node to make it the new center. Scroll to zoom, drag to pan.

The Story So Far

Jan 2026: Raises $18M Series B to expand longevity clinicsJan 2026: Fountain Life offers premium executive physicalsJan 2026: Fountain Life Secures $18M Series B for Longevity Center ExpansionAug 2026: Fountain Life's modest $18M Series B stands out against much larger recent longevity-sect… (unconfirmed)

Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.

Market Intelligence

Unverified

Credibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.

Fountain Life's modest $18M Series B stands out against much larger recent longevity-sector raises

37% confidence

Fountain Life's $18 million Series B is small relative to the $700 million Neko Health closed the same year and Prenuvo's $120 million Series C, which may reflect Fountain Life's already-profitable, membership-fee-funded clinic model requiring less growth capital rather than weaker investor demand, though the comparison could equally reflect a more cautious fundraising strategy.

This is InsightNodes' own comparative interpretation across differently structured companies and business models; none of the cited sources compare Fountain Life's raise size to Neko Health's or Prenuvo's, and the inference about profitability driving the smaller round size is not directly confirmed by Fountain Life's own disclosures.

InsightNodes analysis of longevity-sector funding disclosures · Aug 13, 2026

Fountain Life's Timeline

A sourced, dated history of Fountain Life's key moments — founding to present.

  1. Jan 2026 · Raises $18M Series B to expand longevity clinics

    Fountain Life raised an $18 million Series B round led by EOS Ventures, following an $80 million Series A, bringing total funding to roughly $108 million. Co-founded by Dr. William Kapp, Dr. Peter Diamandis, and Tony Robbins, the company operates centers in Naples, Westchester, Orlando, and Dallas, with planned expansion to Houston, Los Angeles, and Miami.